Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 60

Sort by

Sort Order Select

Journal Articles

Optimizing Molecular Diagnosis of Systemic Mastocytosis in the Era of KIT Tyrosine Kinase Inhibitors: Results of a Survey and of a Nationwide Proficiency Control Round of KIT D816V Mutation Testing Promoted By the RIMA (Rete Italiana MAstocitosi) Association

Blood (2024) 144 (Supplement 1): 7640.

https://doi.org/10.1182/blood-2024-202485

Published: 2024

Journal Articles

CML Patients Who Fail to Achieve ≤ 1% BCR::ABL1 at 12 Months or ≤ 0.1% BCR::ABL1 at 24 Months (major molecular response, MMR) Show Significantly Inferior Survival, but Not Due to CML-Related Deaths: Data from an Italian Real-Life Observational Study

Blood (2024) 144 (Supplement 1): 3155.

https://doi.org/10.1182/blood-2024-207877

Published: 2024

Journal Articles

36-Month Follow-up Results of the Gimema ‘Veritas’ Trial of Front-Line Venetoclax and Rituximab (VenR) in Young and Fit Patients with Chronic Lymphocytic Leukemia and an Adverse Biologic Profile

Blood (2023) 142 (Supplement 1): 1905.

https://doi.org/10.1182/blood-2023-181597

Published: 2023

Journal Articles

Real-World Outcome of Treatment with Single-Agent Ibrutinib in Patients with Chronic Lymphocytic Leukemia: Results from the Italian Study Evidence

Blood (2022) 140 (Supplement 1): 4178–4180.

https://doi.org/10.1182/blood-2022-166140

Published: 2022

Journal Articles

Complex karyotype in unfit patients with CLL treated with ibrutinib and rituximab: the GIMEMA LLC1114 phase 2 study

Blood (2021) 138 (25): 2727–2730.

https://doi.org/10.1182/blood.2021011883

Published: 2021

Includes: Supplemental data

Journal Articles

Novel NPM1 exon 5 mutations and gene fusions leading to aberrant cytoplasmic nucleophosmin in AML

Blood (2021) 138 (25): 2696–2701.

https://doi.org/10.1182/blood.2021012732

Published: 2021

Includes: Supplemental data

Journal Articles

Serological Response Following BNT162b2 Anti-Sars-Cov-2 mRNA Vaccination in Hematopoietic Stem Cell Transplantation Patients

Blood (2021) 138 (Supplement 1): 4875.

https://doi.org/10.1182/blood-2021-147542

Published: 2021

Journal Articles

COVID-19 in Patients with Monoclonal Gammopathy of Undetermined Significance (MGUS): An Observational Retrospective Study

Nicola Sgherza, Paola Curci, Rita Rizzi, Silvio Tafuri, Pasquale Stefanizzi, Vanda Strafella, Daniela Di Gennaro, Angelantonio Vitucci, Antonio Palma, Antonella Vita Russo Rossi, Luigi Vimercati, Francesco Albano, Pellegrino Musto

Blood (2021) 138 (Supplement 1): 2702.

https://doi.org/10.1182/blood-2021-150909

Published: 2021

Journal Articles

The Use of Ibrutinib in Italian CLL Patients Treated in a Real-World Setting (EVIDENCE): A Preliminary Report

Blood (2021) 138 (Supplement 1): 4684.

https://doi.org/10.1182/blood-2021-148378

Published: 2021

Journal Articles

Chronic Lymphocytic Leukemia (CLL) Patients Quality of Life (QoL): A Cross-Sectional Analysis of the Italian Experience in the Choice Study during the First Wave of the COVID-19 Pandemic

Alessandra Tedeschi, Idanna Innocenti, Francesco Albano, Alessandro Gozzetti, Luciano Levato, Marika Porrazzo, Gianluigi Reda, Elisa Albi, Annalisa Chiarenza, Giuliana Gualberti, Simona Malgieri, Paola Finsinger, Livio Trentin

Blood (2021) 138 (Supplement 1): 4680.

https://doi.org/10.1182/blood-2021-150274

Published: 2021

Journal Articles

JAK2 Negative Erythrocytosis Associated with JAK2 GGCC_46/1 Haplotype, Calr rs1049481_G, and Normal Erythropoietin Level: Is This a New Entity?

Antonella Zagaria, Francesco Tarantini, MD, Luisa Anelli, Paola Orsini, Angela Minervini, Nicoletta Coccaro, Elisa Parciante, Crescenzio Francesco Minervini, Cosimo Cumbo, Giuseppina Tota, Luciana Impera, Maria Rosa Conserva, Immacolata Redavid, Alessandra Ricco, MD, Immacolata Attolico, MD, Giorgina Specchia, MD, Pellegrino Musto, MD, Francesco Albano

Blood (2020) 136 (Supplement 1): 28.

https://doi.org/10.1182/blood-2020-139450

Published: 2020

Journal Articles

Low Cholesterol, Low-Density Lipoprotein (LDL) and Triglycerides Plasma Levels Are Associated with Lower Risk of Arterial Occlusive Events in Chronic Myeloid Leukemia Patients Treated with Nilotinib

Blood (2020) 136 (Supplement 1): 8–9.

https://doi.org/10.1182/blood-2020-134496

Published: 2020

Journal Articles

Predictive Factors for Overall Survival in Chronic Myeloid Leukemia Patients: An Analysis By the Gimema Cml Italian Study

Giorgina Specchia, MD, Patrizia Pregno, Massimo Breccia, MD, Chiara Monagheddu, Fausto Castagnetti, MDPhD, Massimiliano Bonifacio, MD, Mario Tiribelli, MD, Fabio Stagno, MD PhD, Giovanni Caocci, MD, Bruno Martino, MD, Luigiana Luciano, MD, Michele Pizzuti, MD, Antonella Gozzini, MD, Anna Rita Scortechini, MD, Francesco Albano, Micaela Bergamaschi, MD, Isabella Capodanno, MD, Andrea Patriarca, MD, Carmen Fava, Giovanna Rege Cambrin, MDPhD, Federica Sorà, MD, Sara Galimberti, MD PhD, Monica Bocchia, Gianni Binotto, MD, Giovanni Reddiconto, Attilio Guarini, MD, Alessandro Maggi, Grazia Sanpaolo, MD, Maria Stella De Candia, Valentina Giai, MD PhD, Elisabetta Abruzzese, MD, Maria Cristina Miggiano, MD, Franca Falzetti, MD, Gaetano La Barba, Giuseppe Pietrantuono, Anna Guella, MD, Luciano Levato, MD, Olga Mulas, Fabio Saccona, Gianantonio Rosti, MD, Pellegrino Musto, MD, Francesco Di Raimondo, MD, Fabrizio Pane, MD, Robin Foà, MD, Michele Baccarani, MD, Giovannino Ciccone, Giuseppe Saglio, MD PhD

Blood (2020) 136 (Supplement 1): 47–48.

https://doi.org/10.1182/blood-2020-139307

Published: 2020

Journal Articles

A Preliminary Analysis of FLAM (Italian Non-Interventional Multi-center Study of FLT3 mutated AML patients): FLT3 Receptor Gene Mutational Analysis and FLT3 Inhibitors Administration in the Real-Life Clinical Practice

Blood (2020) 136 (Supplement 1): 32–34.

https://doi.org/10.1182/blood-2020-139981

Published: 2020

Journal Articles

Efficacy and Safety of Front-Line Venetoclax and Rituximab (VenR) for the Treatment of Young Patients with Chronic Lymphocytic Leukemia and an Unfavorable Biologic Profile. Preliminary Results of the Gimema Study 'Veritas'

Francesca Romana Mauro, MD PhD, Gianluigi Reda, MD, Valentina Arena, MS, Livio Trentin, MD, Marta Coscia, MD PhD, Paolo Sportoletti, MD, Luca Laurenti, MD, Gianluca Gaidano, Roberto Marasca, MD, Lorella Orsucci, MD, Roberta Murru, MD, Caterina Stelitano, Fiorella Ilariucci, MD, Donato Mannina, MD, Massimo Massaia, MD, Gian Matteo Rigolin, Lydia Scarfo, Monia Marchetti, MD, Luciano Levato, MD, Monica Tani, MD, Annalisa Arcari, MD, Gerardo Musuraca, MD, Marina Deodato, Piero Galieni, Catello Califano, MD, Daniela Gottardi, MD, Anna Marina Liberati, MD, Daniela Pietrasanta, MD, Stefano Molica, MD, Ramona Cassin, MD, Andrea Visentin, MDPhD, Candida Vitale, MDPhD, Gianfranco Lapietra, MD, Irene Della Starza, PhD, Maria Stefania De Propris, PhD, Sara Raponi, PhD, Mauro Nanni, PhD, Ilaria Del Giudice, MD PhD, Giorgia Giuliani, PhD, Marco Vignetti, MD, Anna Guarini, PhD, Francesco Albano, Antonino Neri, MD, Antonio Cuneo, MD, Robin Foà, MD

Blood (2020) 136 (Supplement 1): 47–49.

https://doi.org/10.1182/blood-2020-135922

Published: 2020

Journal Articles

Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: the NEXT-in-CML study

Simona Soverini, Luana Bavaro, Caterina De Benedittis, Margherita Martelli, Alessandra Iurlo, Nicola Orofino, Simona Sica, Federica Sorà, Francesca Lunghi, Fabio Ciceri, Sara Galimberti, Claudia Baratè, Massimiliano Bonifacio, Luigi Scaffidi, Fausto Castagnetti, Gabriele Gugliotta, Francesco Albano, Antonella Vita Russo Rossi, Fabio Stagno, Francesco di Raimondo, Mariella D’Adda, Eros di Bona, Elisabetta Abruzzese, Gianni Binotto, Rosaria Sancetta, Marzia Salvucci, Isabella Capodanno, Mariella Girasoli, Sabrina Coluzzi, Immacolata Attolico, Caterina Musolino, Elisabetta Calistri, Mario Annunziata, Monica Bocchia, Stefania Stella, Anna Serra, Santa Errichiello, Giuseppe Saglio, Fabrizio Pane, Paolo Vigneri, Flavio Mignone, Maria Antonella Laginestra, Stefano Aldo Pileri, Antonio Percesepe, Elena Tenti, Gianantonio Rosti, Michele Baccarani, Michele Cavo, Giovanni Martinelli

Blood (2020) 135 (8): 534–541.

https://doi.org/10.1182/blood.2019002969

Published: 2020

Includes: Supplemental data

Journal Articles

Multicenter, Prospective and Retrospective Observational Cohort Study of Ponatinib in Patients with CML in Italy: Interim Analysis of the OITI Trial

Alessandra Iurlo, MD PhD, Mario Annunziata, MD, Francesco Albano, MD, Luigia Luciano, MD, Raffaele Spadano, MD, Anna Rita Scortechini, MD, Massimiliano Bonifacio, MD, Elisabetta Abruzzese, MD, Monia Lunghi, MD PhD, Alessandra Malato, MD PhD, Nicola Di Renzo, MD, Alfonso Piciocchi, Angela Pellegrino, MSc, Claudia Galimberti, Robin Foà, MD, Massimo Breccia, MD

Blood (2019) 134 (Supplement_1): 1652.

https://doi.org/10.1182/blood-2019-126098

Published: 2019

Journal Articles

Impact of Bone Marrow Fibrosis Grade in Post-Polycythemia Vera and Post-Essential Thrombocythemia Myelofibrosis. a Study of the Mysec Group

Blood (2019) 134 (Supplement_1): 2946.

https://doi.org/10.1182/blood-2019-124854

Published: 2019

Journal Articles

Aurora Kinase a/MDM2-Mediated SETD2 Loss of Function in Chronic Myeloid Leukemia Patients in Blast Crisis Can be Therapeutically Targeted Inducing Apoptotic Cell Death in a Caspase-Dependent Way

Blood (2019) 134 (Supplement_1): 4142.

https://doi.org/10.1182/blood-2019-126500

Published: 2019

Journal Articles

Ten-Year Follow-up of Patients with Chronic Myeloid Leukemia Treated with Nilotinib in First-Line: Final Results of the Gimema CML 0307 Trial

Blood (2019) 134 (Supplement_1): 4145.

https://doi.org/10.1182/blood-2019-126163

Published: 2019

NARROW

Optimizing Molecular Diagnosis of Systemic Mastocytosis in the Era of KIT Tyrosine Kinase Inhibitors: Results of a Survey and of a Nationwide Proficiency Control Round of KIT D816V Mutation Testing Promoted By the RIMA (Rete Italiana MAstocitosi) Association

CML Patients Who Fail to Achieve ≤ 1% BCR::ABL1 at 12 Months or ≤ 0.1% BCR::ABL1 at 24 Months (major molecular response, MMR) Show Significantly Inferior Survival, but Not Due to CML-Related Deaths: Data from an Italian Real-Life Observational Study

36-Month Follow-up Results of the Gimema ‘Veritas’ Trial of Front-Line Venetoclax and Rituximab (VenR) in Young and Fit Patients with Chronic Lymphocytic Leukemia and an Adverse Biologic Profile

Real-World Outcome of Treatment with Single-Agent Ibrutinib in Patients with Chronic Lymphocytic Leukemia: Results from the Italian Study Evidence

Complex karyotype in unfit patients with CLL treated with ibrutinib and rituximab: the GIMEMA LLC1114 phase 2 study

Novel NPM1 exon 5 mutations and gene fusions leading to aberrant cytoplasmic nucleophosmin in AML

Serological Response Following BNT162b2 Anti-Sars-Cov-2 mRNA Vaccination in Hematopoietic Stem Cell Transplantation Patients

COVID-19 in Patients with Monoclonal Gammopathy of Undetermined Significance (MGUS): An Observational Retrospective Study

The Use of Ibrutinib in Italian CLL Patients Treated in a Real-World Setting (EVIDENCE): A Preliminary Report

Chronic Lymphocytic Leukemia (CLL) Patients Quality of Life (QoL): A Cross-Sectional Analysis of the Italian Experience in the Choice Study during the First Wave of the COVID-19 Pandemic

JAK2 Negative Erythrocytosis Associated with JAK2 GGCC_46/1 Haplotype, Calr rs1049481_G, and Normal Erythropoietin Level: Is This a New Entity?

Low Cholesterol, Low-Density Lipoprotein (LDL) and Triglycerides Plasma Levels Are Associated with Lower Risk of Arterial Occlusive Events in Chronic Myeloid Leukemia Patients Treated with Nilotinib

Predictive Factors for Overall Survival in Chronic Myeloid Leukemia Patients: An Analysis By the Gimema Cml Italian Study

A Preliminary Analysis of FLAM (Italian Non-Interventional Multi-center Study of FLT3 mutated AML patients): FLT3 Receptor Gene Mutational Analysis and FLT3 Inhibitors Administration in the Real-Life Clinical Practice

Efficacy and Safety of Front-Line Venetoclax and Rituximab (VenR) for the Treatment of Young Patients with Chronic Lymphocytic Leukemia and an Unfavorable Biologic Profile. Preliminary Results of the Gimema Study 'Veritas'

Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: the NEXT-in-CML study

Multicenter, Prospective and Retrospective Observational Cohort Study of Ponatinib in Patients with CML in Italy: Interim Analysis of the OITI Trial

Impact of Bone Marrow Fibrosis Grade in Post-Polycythemia Vera and Post-Essential Thrombocythemia Myelofibrosis. a Study of the Mysec Group

Aurora Kinase a/MDM2-Mediated SETD2 Loss of Function in Chronic Myeloid Leukemia Patients in Blast Crisis Can be Therapeutically Targeted Inducing Apoptotic Cell Death in a Caspase-Dependent Way

Ten-Year Follow-up of Patients with Chronic Myeloid Leukemia Treated with Nilotinib in First-Line: Final Results of the Gimema CML 0307 Trial

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only